LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
LAURA 研究完成了奥希替尼治疗 EGFR+ NSCLC 从 IB 期到 IV 期的拼图：与安慰剂相比，辅助奥希替尼治疗显著改善了不可切除的 III 期 EGFR 突变 NSCLC 患者的 PFS 和 CNS 进展（LAURA，NCT03521154）
期刊:Lung Cancer: Targets and Therapy
影响因子:3.3
doi:10.2147/LCTT.S520833
Luo, Faustine X; Arter, Zhaohui; Ou, Sai-Hong Ignatius; Nagasaka, Misako
